



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Approved for use through 07/31/2006. OMB 0651-0031

PTO/SB/08A (08-03)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 5

Application Number	10/539,093
Filing Date	15 June 2005
First Named Inventor	John M. YANNI
Art Unit	1632
Examiner Name	
Attorney Docket Number	2394 US F

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
AS	A1	US- 3,991,759	11-16-1976	Urquhart	
	A2	US- 4,131,651	12-26-1978	Shah et al.	
	A3	US- 4,370,325	01-25-1983	Packman	
	A4	US- 4,409,205	10-11-1983	Shively	
	A5	US- 4,744,980	05-17-1988	Holly	
	A6	US- 4,753,945	06-28-1988	Gilbard et al.	
	A7	US- 4,818,537	04-04-1989	Guo	
	A8	US- 4,868,154	09-19-1989	Holly	
	A9	US- 4,914,088	04-03-1990	Glonetek et al.	
	A10	US- 4,966,773	10-30-1990	Gressel et al.	
	A11	US- 5,041,434	08-20-1991	Lubkin	
	A12	US- 5,075,104	12-24-1991	Gressel et al.	
	A13	US- 5,174,988	12-29-1992	Mautone et al.	
	A14	US- 5,278,151	01-11-1994	Korb et al.	
	A15	US- 5,290,572	03-01-1994	MacKeen	
	A16	US- 5,294,607	03-15-1994	Glonetek et al.	
AS	A17	US- 5,371,108	12-06-1994	Korb et al.	
	A18	US- 5,403,841	04-04-1995	Lang et al.	
	A19	US- 5,455,265	10-03-1995	Chandraratna	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	A20					
	A21					
	A22					
	A23					
	A24					
	A25					

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (07-05)

Approved for use through 07/31/2006, OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Privacy Act of 1974, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

Application Number	10/539,093
Filing Date	15 June 2005
First Named Inventor	John M. YANNI
Art Unit	1632
Examiner Name	
Attorney Docket Number	2394 US F

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	/Anoop Singh/	Date Considered	01/02/2007
-----------------------	---------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Upon completion of the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 5 Attorney Docket Number 2394 US F

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AS	B1	BARABINO S and DANA MR (2004). Animal models of dry eye: a critical assessment of opportunities and limitations. 45(6): 1641-1646	
	B2	BEHRENS et al. (2002). Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze. IOVS 43(4): 968-977	
	B3	BRASH et al., "Discovery of a second 15S-lipoxygenase in humans", PROC. NATL. ACAD. SCI. USA 94:6148-6152 (1997)	
	B4	DARTT et. al., "Vasoactive Intestinal Peptide-Stimulated Glycoconjugate Secretion from Conjunctival Goblet Cells", EXPERIMENTAL EYE RESEARCH 63:27-33, (1996)	
	B5	DILLY et al., "Surface changes in the anaesthetic conjunctiva in man, with special reference to the production of mucus from a non-goblet-cell source", BRITISH JOURNAL OF OPHTHALMOLOGY 65:833-842 (1981).	
	B6	GREINER et al., "Mucus Secretory Vesicles in Conjunctival Epithelial Cells of Wearers of Contact Lenses", ARCHIVES OF OPHTHALMOLOGY 98:1843-1846 (1980)	
	B7	HSI et al., "Evaluation of the activity and localization of 15-Lipoxygenase-1 after introduction into human colorectal carcinoma Caco-2 cells", PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS 64 (4 & 5):217-225 (2001)	
	B8	HSI et al., "Opposing Effects of 15-Lipoxygenase-1 and -2 Metabolites on MAPK Signaling in Prostate", THE JOURNAL OF BIOLOGICAL CHEMISTRY 277(43):40549-40556 (2002)	
▼	B9	International Search Report for PCT/US03/33139 [#2394 WO F]	
AS	B10	KAMATA et al. (2001). Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII. MOLECULAR THERAPY 4(4): 307-312	

Examiner Signature	/Anoop Singh/	Date Considered	01/02/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number. *Complete if known*

Complete if Known

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 5 Attorney Docket Number 2394 US F

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AS	C1	LEMP, "Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes", The CLAO Journal, 21(4):221-232 (1995)	
	C2	LIMINGA et al (1994). Arachidonate 15-lipoxygenase in human corneal epithelium and 12- and 15-lipoxygenases in bovine corneal epithelium: comparison with other bovine 12-lipoxygenases. Biochim Biophys Acta. 1210(3): 288-296	
	C3	LIMINGA and OLIW, "Qualitative and Quantitative Analysis of Lipoxygenase Products in Bovine Corneal Epithelium by Liquid Chromatography-Mass Spectrometry with an Ion Trap", LIPIDS 35 (2):225-232 (2000)	
	C4	MAROM et al., "Human Airway Monohydroxyeicosatetraenoic Acid Generation and Mucus Release", JOURNAL OF CLINICAL INVESTIGATION 72:122-127 (1983)	
	C5	MARTIN et al. (2002). Gene delivery to the eye using adeno-associated viral vectors, METHODS 28 267-275	
	C6	MCCULLEY and SHINE, "Tear Film Structure and Dry Eye", Contactologia, 20(4):145-49 (1998)	
	C7	NAKMURA et. al., "Gefarnate Stimulates Secretion of Mucin-Like Glycoproteins by Corneal Epithelium in Vitro and Protects Corneal Epithelium from Desiccation in Vivo", EXPERIMENTAL EYE RESEARCH 65:569-574 (1997)	
	C8	PETERSON CM et al. (2002). Dry eye syndrome in postmenopausal women. JAMA 287(5): 585-586	
▼	C9	PFEIFER A and VERMA IM (2001). Gene Therapy: promises and problems. Annu Rev Genomics Hum Genet. 2: 177-211	
AS	C10	SHAPPELL et al., "15-Lipoxygenase-2 (15-LOX-2) Is Expressed in Benign Prostatic Epithelium and Reduced in Prostate Adenocarcinoma", AMER. J. PATH. 155(1):235-245 (1999)	

Examiner Signature	/Anoop Singh/	Date Considered	01/02/2007
-----------------------	---------------	--------------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Application's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English is not your native language. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	5	of	5	Attorney Docket Number	2394 US F

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AS	D1	SHAPPELL et al., "15-Lipoxygenase-2 Expression in Benign and Neoplastic Sebaceous Glands and Other Cutaneous Adnexa", J. INVESTIGATIVE DERMATOLOGY. 117(1):36-43 (2001)	
	D2	SHINE and MCCULLEY, "Keratoconjunctivitis Sicca Associated With Meibomian Secretion Polar Lipid Abnormality", ARCHIVES OF OPHTHALMOLOGY 116(7):849-52 (1998)	
	D3	STECHSCHULTE et al., "Rapid Ocular Angiogenic Control via Naked DNA Delivery to Cornea", INVEST. OPHTHALMOL. VIS. SCI. 42(9):1975-1979 (2001)	
	D4	VERMA, I. M. and SOMIA, N. (1997). Gene therapy-promises, problems and prospects. NATURE 389: 239-242	
↓	D5	WATANABE et al., "Human Corneal and Conjunctival Epithelia Produce a Mucin-like Glycoprotein for the Apical Surface", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE 36(2):337-344 (1995)	
AS	D6	YANNI et al, "Effect of Intravenously Administered Lipoxygenase Metabolites on Rat Tracheal Mucous Gel Layer Thickness", INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY 90:307-309 (1989)	
	D7		
	D8		
	D9		
	D10		

Examiner Signature	/Anoop Singh/	Date Considered	01/02/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.